Inozyme Pharma (INZY) News Today $3.97 -0.01 (-0.25%) Closing price 04:00 PM EasternExtended Trading$3.98 +0.00 (+0.13%) As of 04:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock INZY Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Inozyme Pharma Reports Increased Loss Amid Strategic FocusJune 9 at 11:56 PM | tipranks.comInozyme Pharma, Inc. (NASDAQ:INZY) Given Consensus Recommendation of "Hold" by AnalystsJune 9 at 1:19 AM | americanbankingnews.comInozyme Pharma, Inc. (NASDAQ:INZY) Receives Consensus Recommendation of "Hold" from BrokeragesInozyme Pharma, Inc. (NASDAQ:INZY - Get Free Report) has earned an average rating of "Hold" from the nine research firms that are covering the company, Marketbeat.com reports. Five investment analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The avJune 9 at 1:17 AM | marketbeat.comReviewing Oncternal Therapeutics (NASDAQ:ONCT) & Inozyme Pharma (NASDAQ:INZY)June 4, 2025 | americanbankingnews.comMillennium Management LLC Has $5.21 Million Stake in Inozyme Pharma, Inc. (NASDAQ:INZY)Millennium Management LLC raised its stake in shares of Inozyme Pharma, Inc. (NASDAQ:INZY - Free Report) by 7.9% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,882,274 shares of the company's stock after buying an additMay 30, 2025 | marketbeat.comBMRN to Acquire Inozyme PharmaMay 22, 2025 | finance.yahoo.comINOZYME PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inozyme Pharma, Inc. - INZYMay 21, 2025 | businesswire.comJacobs Levy Equity Management Inc. Takes Position in Inozyme Pharma, Inc. (NASDAQ:INZY)Jacobs Levy Equity Management Inc. acquired a new stake in shares of Inozyme Pharma, Inc. (NASDAQ:INZY - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 129,749 shares of the company's stock, vMay 20, 2025 | marketbeat.comCubist Systematic Strategies LLC Acquires New Stake in Inozyme Pharma, Inc. (NASDAQ:INZY)Cubist Systematic Strategies LLC acquired a new stake in shares of Inozyme Pharma, Inc. (NASDAQ:INZY - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 83,919 shares of the company's stock, valued at approximately $232,000. CMay 20, 2025 | marketbeat.com443,255 Shares in Inozyme Pharma, Inc. (NASDAQ:INZY) Acquired by SanofiSanofi purchased a new stake in Inozyme Pharma, Inc. (NASDAQ:INZY - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 443,255 shares of the company's stock, valued at approximately $1,228May 19, 2025 | marketbeat.comInozyme Pharma (NASDAQ:INZY) Stock Rating Lowered by Needham & Company LLCNeedham & Company LLC downgraded shares of Inozyme Pharma from a "moderate buy" rating to a "hold" rating in a report on Friday.May 19, 2025 | marketbeat.comInozyme Pharma (NASDAQ:INZY) Downgraded to "Hold" Rating by WedbushWedbush downgraded shares of Inozyme Pharma from a "strong-buy" rating to a "hold" rating in a research note on Friday.May 19, 2025 | marketbeat.comJefferies Downgrades Inozyme Pharma (INZY)May 17, 2025 | msn.comNeedham Downgrades Inozyme Pharma (INZY)May 17, 2025 | msn.comLeerink bullish on BioMarin following Inozyme deal, expects additional BDMay 17, 2025 | finance.yahoo.comInozyme Pharma, Inc. (NASDAQ:INZY) Given Consensus Recommendation of "Buy" by BrokeragesInozyme Pharma, Inc. (NASDAQ:INZY - Get Free Report) has received a consensus rating of "Buy" from the eight brokerages that are covering the firm, MarketBeat reports. Eight research analysts have rated the stock with a buy rating. The average twelve-month target price among brokerages that have iMay 17, 2025 | marketbeat.comInozyme Shares More Than Double in Surge Toward BioMarin's Buyout PriceMay 16, 2025 | marketwatch.comBioMarin stock rises following Inozyme Pharma acquisitionMay 16, 2025 | in.investing.comBioMarin to buy enzyme therapy developer Inozyme in $270M all-cash dealMay 16, 2025 | msn.comInozyme Stock Rockets 179% After BioMarin Agrees To Acquire The Company For $270M: Retail Sentiment BrightensMay 16, 2025 | msn.comSHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Inozyme Pharma, Inc. - INZYMay 16, 2025 | prnewswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CHTR and INZY on Behalf of ShareholdersMay 16, 2025 | prnewswire.comINZY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Inozyme Pharma, Inc. Is Fair to ShareholdersMay 16, 2025 | businesswire.comShareholder Alert: The Ademi Firm investigates whether Inozyme Pharma, Inc. is obtaining a Fair Price for its Public ShareholdersMay 16, 2025 | businesswire.comBioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme PharmaMay 16, 2025 | prnewswire.comInozyme Pharma Reports First Quarter 2025 Financial Results and Provides Business HighlightsMay 14, 2025 | finance.yahoo.comInozyme Pharma Reports First Quarter 2025 Financial Results and Provides Business HighlightsMay 14, 2025 | globenewswire.comRenaissance Technologies LLC Buys 256,599 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY)Renaissance Technologies LLC grew its stake in shares of Inozyme Pharma, Inc. (NASDAQ:INZY - Free Report) by 155.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 421,399 shares of the company's stock aftMay 2, 2025 | marketbeat.comInozyme Pharma (INZY) to Release Quarterly Earnings on TuesdayInozyme Pharma (NASDAQ:INZY) will be releasing its Q1 2025 earnings before the market opens on Tuesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-6-inozyme-pharma-inc-stock/)May 1, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Has $14.29 Million Stock Position in Inozyme Pharma, Inc. (NASDAQ:INZY)Adage Capital Partners GP L.L.C. lowered its stake in Inozyme Pharma, Inc. (NASDAQ:INZY - Free Report) by 9.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 5,160,000 shares of the company's stock after selling 513,629 shares during the period.April 30, 2025 | marketbeat.comInozyme Pharma, Inc. (NASDAQ:INZY) Receives Consensus Rating of "Buy" from BrokeragesShares of Inozyme Pharma, Inc. (NASDAQ:INZY - Get Free Report) have received an average recommendation of "Buy" from the eight research firms that are presently covering the company, MarketBeat.com reports. Eight investment analysts have rated the stock with a buy rating. The average 12 month pricApril 21, 2025 | marketbeat.comAffinity Asset Advisors LLC Raises Holdings in Inozyme Pharma, Inc. (NASDAQ:INZY)Affinity Asset Advisors LLC lifted its holdings in Inozyme Pharma, Inc. (NASDAQ:INZY - Free Report) by 40.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,972,318 shares of the company's stock after purchasing anApril 17, 2025 | marketbeat.comInozyme announces JBMR Plus publication on ENPP1 deficiencyApril 11, 2025 | markets.businessinsider.comInozyme Pharma (NASDAQ:INZY) Given Buy Rating at Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and issued a $15.00 price target on shares of Inozyme Pharma in a report on Tuesday.April 10, 2025 | marketbeat.comInozyme Pharma Announces JBMR Plus Publication Demonstrating Real-World Impact of ENPP1 DeficiencyApril 10, 2025 | globenewswire.comInozyme Pharma Announces JBMR Plus Publication Demonstrating Real-World Impact of ENPP1 DeficiencyApril 10, 2025 | globenewswire.comInozyme Pharma to Participate in the 24th Annual Needham Virtual Healthcare ConferenceMarch 31, 2025 | globenewswire.comInozyme Pharma (INZY) Gets a Buy from Bank of America SecuritiesMarch 17, 2025 | markets.businessinsider.comHC Wainwright Boosts Earnings Estimates for Inozyme PharmaInozyme Pharma, Inc. (NASDAQ:INZY - Free Report) - Investment analysts at HC Wainwright increased their FY2027 EPS estimates for shares of Inozyme Pharma in a research report issued on Tuesday, March 11th. HC Wainwright analyst E. White now anticipates that the company will earn ($0.73) per shareMarch 15, 2025 | marketbeat.comQ1 EPS Estimates for Inozyme Pharma Decreased by AnalystInozyme Pharma, Inc. (NASDAQ:INZY - Free Report) - HC Wainwright decreased their Q1 2025 earnings per share (EPS) estimates for Inozyme Pharma in a report released on Tuesday, March 11th. HC Wainwright analyst E. White now forecasts that the company will earn ($0.44) per share for the quarter, doMarch 14, 2025 | marketbeat.comQ1 Earnings Estimate for Inozyme Pharma Issued By WedbushInozyme Pharma, Inc. (NASDAQ:INZY - Free Report) - Analysts at Wedbush issued their Q1 2025 earnings per share (EPS) estimates for Inozyme Pharma in a report issued on Monday, March 10th. Wedbush analyst D. Nierengarten anticipates that the company will post earnings of ($0.43) per share for theMarch 14, 2025 | marketbeat.comRaymond James Cuts Inozyme Pharma (NASDAQ:INZY) Price Target to $12.00Raymond James dropped their price objective on shares of Inozyme Pharma from $24.00 to $12.00 and set an "outperform" rating for the company in a report on Wednesday.March 13, 2025 | marketbeat.comInozyme Pharma (NASDAQ:INZY) Given New $23.00 Price Target at Piper SandlerPiper Sandler decreased their price objective on shares of Inozyme Pharma from $30.00 to $23.00 and set an "overweight" rating on the stock in a report on Tuesday.March 12, 2025 | marketbeat.comInozyme price target lowered to $12 from $24 at Raymond JamesMarch 12, 2025 | markets.businessinsider.comInozyme Pharma (NASDAQ:INZY) Price Target Cut to $15.00 by Analysts at Needham & Company LLCNeedham & Company LLC reduced their target price on Inozyme Pharma from $23.00 to $15.00 and set a "buy" rating on the stock in a research note on Tuesday.March 12, 2025 | marketbeat.comHC Wainwright Reaffirms Buy Rating for Inozyme Pharma (NASDAQ:INZY)HC Wainwright reiterated a "buy" rating and issued a $16.00 target price on shares of Inozyme Pharma in a research note on Tuesday.March 12, 2025 | marketbeat.comWedbush Reaffirms Outperform Rating for Inozyme Pharma (NASDAQ:INZY)Wedbush reissued an "outperform" rating and set a $7.00 price objective (down from $12.00) on shares of Inozyme Pharma in a report on Monday.March 11, 2025 | marketbeat.comInozyme Pharma Focuses on ENPP1 Deficiency ProgramMarch 11, 2025 | tipranks.comAnalysts Offer Insights on Healthcare Companies: Inozyme Pharma (INZY) and Urogen Pharma (URGN)March 10, 2025 | markets.businessinsider.comInozyme reports prioritization of ENPP1 Deficiency program, workforce reductionMarch 10, 2025 | markets.businessinsider.com Get Inozyme Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for INZY and its competitors with MarketBeat's FREE daily newsletter. Email Address INZY Media Mentions By Week INZY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. INZY News Sentiment▼0.541.01▲Average Medical News Sentiment INZY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. INZY Articles This Week▼42▲INZY Articles Average Week Get Inozyme Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for INZY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Akebia Therapeutics News CureVac News Enliven Therapeutics News Phibro Animal Health News Collegium Pharmaceutical News Avadel Pharmaceuticals News CorMedix News Nurix Therapeutics News Syndax Pharmaceuticals News Pharvaris News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:INZY) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inozyme Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inozyme Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy INZY Stock Free INZY Stock Alerts